Last Price
16.50
Today's Change
+2.10 (14.61%)
Day's Change
14.60 - 16.54
Trading Volume
982,613
Overview
Market Cap
2 Billion
Shares Outstanding
127 Million
Avg Volume
521,765
Avg Price (50 Days)
13.53
Avg Price (200 Days)
18.25
PE Ratio
17.33
EPS
0.95
Earnings Announcement
29-Jan-2025
Previous Close
14.40
Open
14.85
Day's Range
14.6 - 16.54
Year Range
12.02 - 25.95
Trading Volume
985,981
Price Change Highlight
1 Day Change
14.31%
5 Day Change
34.92%
1 Month Change
15.92%
3 Month Change
-3.69%
6 Month Change
-18.72%
Ytd Change
-33.68%
1 Year Change
29.10%
3 Year Change
824.72%
5 Year Change
540.47%
10 Year Change
955.13%
Max Change
188.27%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Apps
Top Articles
1
CEO Morning Brief
2
CEO Morning Brief
RBA Holds Key Rate at 13-year High as World Waits on US Vote
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
